RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

NaviCap (Direct Drug Delivery Capsule)

Product
Developers: Biora Therapeutics
Date of the premiere of the system: July 2024
Branches: Pharmaceuticals, Medicine, Healthcare

2024: Product Announcement

On July 1, 2024, Biora Therapeutics announced the development of a swallowed NaviCap device, a special capsule designed to deliver drugs directly to the ulcer. This approach allows you to increase the effectiveness of therapy.

NaviCap is aimed at treating ulcerative colitis. This is an inflammatory disease of the mucous membrane of the large intestine, which is severe chronic in nature. Signs of the disease are diarrhea, intestinal bleeding, severe abdominal pain, decreased appetite, general weakness, etc. The disease develops as a result of a combination of several factors, including genetic predisposition, pathological intestinal microflora, unfavorable environment, etc.

NaviCap capsule

NaviCap uses BT-600, a proprietary liquid form of tofacitinib, which is a member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis. The capsule provides delivery of the substance directly to the site of inflammation.

After ingestion, the GItrac automatic location technology in NaviCap helps autonomously identify target locations in the gastrointestinal tract. NaviCap then releases a therapeutic dose of 500 μl. This method increases therapeutic activity in tissues while reducing systemic uptake.

File:Aquote1.png
Our anatomically targeted approach could potentially increase the efficacy of JAK inhibitors and other drug classes. We believe that NaviCap-based technology will open up new treatment opportunities for patients with gastrointestinal diseases, "says Adi Mohanty, CEO of Biora Therapeutics.[1]
File:Aquote2.png

Notes